Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality globally, comprising 80% of all lung cancers.
• Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are prevalent in aggressive lung adenocarcinomas, driving tumorigenesis.
• Despite advances, median survival for advanced lung cancer remains poor (<15% 5-year survival), with no approved therapies for KRAS-mutant NSCLC.

Purpose of the Study:

• To review current knowledge on KRAS-mutated NSCLC.
• To discuss the clinical significance of KRAS as a prognostic and predictive biomarker.
• To emphasize emerging therapeutic strategies for KRAS-variant NSCLC.

Main Methods:

• Literature review of scientific articles and clinical trial data.
• Analysis of KRAS mutation prevalence and clinical impact in NSCLC.
• Synthesis of information on novel therapeutic targets and agents.

Main Results:

• KRAS is a critical oncogene in lung adenocarcinoma, frequently mutated and associated with poor prognosis.
• KRAS mutations serve as important biomarkers for patient stratification and treatment selection.
• Several novel therapeutic approaches targeting KRAS pathways are under investigation.

Conclusions:

• KRAS-mutated NSCLC presents a significant therapeutic challenge due to the lack of targeted drugs.
• Understanding KRAS biology and its role as a biomarker is crucial for developing effective treatments.
• Ongoing research into novel therapies offers hope for improved outcomes in patients with KRAS-mutant NSCLC.